APG 157
Alternative Names: APG-157Latest Information Update: 16 Sep 2025
At a glance
- Originator Aveta Biomics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Head and neck cancer; Oropharyngeal dysplasia; Squamous cell cancer
- Phase I/II Glioblastoma
Most Recent Events
- 30 May 2025 Efficacy and adverse events data from a phase II trial in Head and neck cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology(ASCO-2025)
- 30 May 2025 Efficacy and adverse events data from phase II clinical trials in Oropharyngeal dysplasia presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 19 Dec 2024 Phase-I clinical trials in Head and neck cancer (Recurrent, Metastatic disease, Combination therapy) (PO) (Aveta Biomics pipeline, December 2024)